Journal of Clinical Oncology
Articles in this Issue
Global evolution of HER2-targeted clinical trials across solid tumors: Shifts in tumor representation, biomarker definitions, therapeutic modalities, and geographic leadership.
e23085 Background: HER2 has expanded from a breast-restricted biomarker to a pan-tumor therapeutic target, driven by advan...
Racial disparities in in-hospital outcomes among patients with lung cancer receiving immune checkpoint inhibitors: A National Inpatient Sample analysis.
e23072 Background: Lung cancer is the second most common cancer and the leading cause of cancer-related mortality in the U...
Therapy-related myeloid neoplasms after radioligand therapy in neuroendocrine tumors: A multicenter real-world analysis.
4181 Background: Therapy-related myeloid neoplasms (t-MNs), including myelodysplastic syndrome (MDS) and acute myeloid leu...
Breaking barriers: Evaluation of a low-threshold community-based HPV vaccination model for gender minorities and sex workers in Milan.
1542 Background: Human Papillomavirus (HPV) is the primary etiological factor for anogenital and oropharyngeal cancers. Se...
Learning from the literature: An AI-assisted Bayesian framework for evidence-driven oncology trial design.
e23010 Background: Designing modern oncology trials requires synthesizing prior evidence to inform hypotheses and sample s...
Clinicopathological profile of gastric cancer in a Bolivian cohort: A retrospective analysis from the Instituto Gastroenterológico Boliviano Japonés (2020–2025).
e16022 Background: Gastric cancer remains a leading cause of cancer-related mortality worldwide, particularly in low- and...
Minimal residual disease (MRD) assessment by circulating tumor DNA (ctDNA) to stratify recurrence risk and adjuvant treatment benefit in a real-world colorectal cancer (CRC) cohort.
3616 Background: ctDNA detection following curative surgery is known to predict recurrence in patients (pts) with stage II...
Restrictive eligibility criteria in FDA-approved oncology trials following ASCO Guideline updates.
11020 Background: Despite significant advancements in new targeted and immunotherapies, enrollment in oncology clinical tr...
Trends in lung resection and inpatient mortality among U.S. lung cancer patients (2010–2022).
e23106 Background: Despite declining lung cancer incidence and mortality in the United States, disparities in treatment ut...
Real-world treatment patterns and toxicity of durvalumab after chemoradiation in stage III non-small cell lung cancer.
e20109 Background: Durvalumab following concurrent chemoradiation is the standard of care for patients with unresectable s...
Pathologic complete response in gastric and gastroesophageal adenocarcinoma: Context-dependent survival and CNS-enriched recurrence.
e16141 Background: Although pathologic complete response (pCR) after neoadjuvant therapy is associated with improved outco...
Frailty matters: Association of mFI-5 Index with odds of mortality, hospitalization, and toxicities with ADCs, BiTE, and CAR T-cell therapies in real-world data.
11002 Background: Targeted-delivery biopharmaceuticals such as antibody–drug conjugates (ADCs) or BiTE cell therapy are in...
Cancer-associated type 2 versus type 1 myocardial infarction: A physiology-driven framework for inpatient risk stratification.
e23234 Background: Myocardial injury during cancer hospitalizations is frequently labeled as myocardial infarction, althou...
Clinical outcomes following CAR T-cell therapy in relapsed or refractory multiple myeloma patients with baseline renal dysfunction: A TriNetX analysis.
7539 Background: Renal dysfunction is common in relapsed or refractory multiple myeloma (RRMM) and has historically limite...
Epidemiology, survival disparities, and future incidence projections of small intestine neuroendocrine carcinoma in the United States: A population-based SEER analysis.
e16322 Background: Small intestine neuroendocrine carcinoma (NEC) is a rare, aggressive malignancy comprising less than 0....
Distinct late recurrence patterns and immune landscape of HER2-positive invasive lobular carcinoma (ILC): Analysis of NCCTG N9831 (Alliance) trial and real-world cohort.
564 Background: HER2+ ILC is rare (~5% of ILC), with limited data on long-term adjuvant trastuzumab outcomes. We investiga...
Evaluating the impact of treatment timing with recombinant human thrombopoietin for cancer treatment–induced thrombocytopenia: A retrospective cohort study.
12127 Background: Recombinant human thrombopoietin (rhTPO) is utilized for cancer treatment-induced thrombocytopenia (CTIT...
Malignant ameloblastoma: Real world outcomes of a rare odontogenic malignancy using the SEER database.
e18148 Background: Ameloblastomas are rare odontogenic tumors and represent the second most common neoplasm of odontogenic...
Molecular response and outcomes in patients with myeloproliferative neoplasms treated with interferon in the real-world setting.
6586 Background: Myeloproliferative neoplasms are clonal stem cell disorders driven by constitutive JAK-STAT signaling, cl...
Escape to learn: A team-based gamified educational experience for hematology/oncology fellows.
9021 Background: An escape room is a team-based activity in which participants collaborate to solve puzzles within a fixed...
An open-label phase Ib/II study of trastuzumab deruxtecan combined with nivolumab and CAPOX in patients with HER2-low gastroesophageal adenocarcinoma (EPOC2203).
4024 Background: Trastuzumab deruxtecan (T-DXd) is standard of care for previously treated patients with HER2-positive met...
Access to care and survival outcomes in older adults with chronic lymphocytic leukemia/small lymphocytic lymphoma: A National Cancer Database study.
e19035 Background: Chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) predominantly affect older adults...
Prevalence of the TCF7L2 rs7903146 T allele in young Hispanic adults: Implications for colorectal cancer prevention.
e22650 Background: Colorectal cancer (CRC) incidence has increased in recent years, particularly among young adults, raisi...
Evaluating AI decision support in a rapidly evolving therapeutic landscape: <i>EGFR</i> -mutant metastatic NSCLC.
1630 Background: Large language models (LLM) are increasingly used in oncology, yet may deviate from evidence-based care d...
Real-world outcomes and tumor gene expression analysis of sacituzumab govitecan (SG)- and trastuzumab deruxtecan (T-DXd)-treated metastatic breast cancer (MBC).
1034 Background: While the antibody-drug conjugates (ADCs) SG and T-DXd have transformed MBC care, predictive biomarkers o...